Background
==========

Lifestyle risk factors, especially a high body weight, play an important role in the development of diabetes \[[@B1],[@B2]\]. Due to ongoing ageing and unfavourable trends in lifestyle in the population diabetes prevalence is increasing rapidly \[[@B3],[@B4]\]. Diabetes patients risk a number of micro and macro vascular complications, with 40 to 56% of the patients suffering from one or more of these. Macrovascular complications are responsible for the majority of complication related use of health care and consist of cardiovascular disease and stroke \[[@B5]\]. Prevention aiming at the reduction of cardiovascular risks has therefore the potential to reduce the burden of diabetes \[[@B6],[@B7]\] and is included in current diabetes guidelines. However, given the prevalence of cardiovascular disease in the general population, it seems also worthwhile to introduce similar prevention measures for a broader public \[[@B8]\]. The question thus arises what would be the best strategy: to target cardiovascular prevention to diabetes patients, to invest in prevention strategies intended for the general population, or doing a mix of both?

Part of the answer to this question depends on the relative efficiency of prevention in the general population versus prevention targeting the high risk group of diabetes patients. Numbers needed to treat are lower in diabetes patients, but intervention costs and effectiveness may differ.

Economic evaluations for a range of lifestyle and drug interventions targeting diabetes patients,\[[@B9],[@B10]\] or the general population \[[@B11]-[@B15]\] have been published in recent years. Evaluations of drug interventions dominate, but smoking cessation and overweight reduction have also been evaluated frequently. The majority of these evaluations applied some form of modelling to extrapolate from the short term effects on intermediate outcomes such as quitting smoking, weight reduction and lowering cholesterol levels to the outcome of interest: long term health in terms of mortality and quality of life. Trials with a follow-up long enough to directly measure these outcomes are rare, with the notable exception of the UKPDS \[[@B16]\]. Modelling has the added advantage that several sources may be combined to provide a consistent picture of the best available evidence \[[@B17]\].

However, comparing the outcomes of single evaluations is difficult, among others since they were performed in different countries \[[@B18],[@B19]\]. Furthermore, not all evaluations included all relevant effects of the interventions. Comparability is importantly increased when all interventions are evaluated with the same model in the same setting. Therefore, in this paper, we translated evidence for all interventions to a single setting (that of the Dutch healthcare system) and evaluated them using the same model. This model was developed to capture all relevant health effects of the types of prevention that were evaluated, that is, not only effects on cardiovascular diseases, but also those on other chronic diseases that show increased risks for the risk factors targeted by the preventive interventions. Furthermore, effects of prevention on delaying mortality leading to diseases and costs of care in life years gained were also taken into account \[[@B20],[@B21]\]. This improved the comparability of the outcomes and allowed to analyze the full trade-off between different target groups for prevention.

We show that such a comparison, however, cannot be restricted to cost-effectiveness ratios. While informative, it is clear that a prevention program for the general population with a potential reach of 300,000 people will be valued differently from a program fit for a selective patient group consisting of 30,000 people. In other words, program sizes matter \[[@B22]\].

Mathematical programming models for resource allocation combine the results of cost effectiveness analysis with epidemiological and demographic data, as well as data on program scale to find the optimal allocation of resources over programs. Compared to a cost-effectiveness analysis, the strength of a mathematical programming approach is that program sizes and hence budgetary impact are taken into account. The resulting choices of interventions are different from those guided by cost-effectiveness only.

The approach furthermore allows analyzing the effect of different objectives and constraints, for instance on indivisible programs or equity \[[@B23],[@B24]\]. Resource allocation models for diabetes or its prevention have been undertaken previously \[[@B23],[@B25],[@B26]\]. These studies focused on either primary prevention in the non diabetes population or on prevention of complications for diabetes patients separately. In contrast, the current study aimed to compare both, and used resource allocation modelling to address choices between both types of prevention, considering a range of prevention programs and evaluating them using a model that accounts for the full effects on health and costs of care.

The rest of the paper is structured as follows: first our methods are set out, paying attention to our general approach, the input data that were needed to populate the model as well as the resource allocation model. Second, results are presented in terms of total costs and health benefits that may be obtained from the optimal allocation of a given budget. Finally we discuss the results and their policy implications.

Methods
=======

General approach
----------------

To analyze the trade-off between four types of interventions for the general population and in diabetes patients, the following steps were taken. First, effects of the interventions on intermediate outcomes and intervention costs were estimated. Second, modelling was applied to find long term health effects and effects on healthcare costs, using the same model for all interventions. Third, capacity constraints and demand restrictions that may apply to the interventions were assessed. Fourth, the long term costs and effects were fed into a mathematical programming model, combining them with information on constraints and on population sizes to find optimal allocations for a range of healthcare budgets.

Input data
----------

Details and results of the first two steps have been published for all interventions concerned in separate publications \[[@B27]-[@B32]\]. In short, first interventions were selected based on the available evidence on effectiveness from systematic reviews and their relevance for the Dutch setting. For these interventions effects of the interventions on intermediate outcomes were estimated based on systematic reviews, while intervention costs were calculated using bottom up estimates of resource use and unit costs (Table [1](#T1){ref-type="table"}). Cost data are expressed in euro at price levels 2007.

###### 

Short term costs and effects of interventions (price level 2007)

  -----------------------------------------------------------------------------------------------------------------------------------------
  Intervention                                                                     Effectiveness\*    **Annual costs per participant**^†^
  -------------------------------------------------------------------------------- ------------------ -------------------------------------
  *General population*                                                                                

                                                                                                      

  Minimal cessation counseling by GP                                               28                 €30

                                                                                                      

  Intensive smoking cessation counseling plus pharmacotherapy                      68                 €420

                                                                                                      

  Minimal lifestyle intervention, community intervention (Hartslag Limburg^‡^)     Activity: 0-1\     €6
                                                                                   Overweight: 5-8    

                                                                                                      

  Intensive lifestyle intervention for persons with extreme overweight (SLIM^§^)   Activity: 1-6\     €700
                                                                                   Overweight: 18.    

                                                                                                      

  Medication to reduce blood pressure for persons with SBP \> 140                  390                €1200-€280\*\*

                                                                                                      

  Statins for persons with total cholesterol \> 6.5                                470                €1500-€3700\*\*

                                                                                                      

  *Diabetes patients*                                                                                 

                                                                                                      

  Minimal cessation counseling by GP                                               28                 €30

                                                                                                      

  Intensive smoking cessation counseling plus pharmacotherapy                      68                 €420

                                                                                                      

  Minimal lifestyle intervention (X-PERT^††^)                                      Activity: 50-90\   €120
                                                                                   Overweight: 35     

                                                                                                      

  Intensive lifestyle intervention (LookAHEAD^‡‡^)                                 Overweight: 140    €500

                                                                                                      

  Medication to reduce blood pressure for persons with SBP \> 140^§§^              390                €1000-€3300\*\*

                                                                                                      

  Statins for al diabetes patients\*\*\*                                           470                €1100-€3800 \*\*
  -----------------------------------------------------------------------------------------------------------------------------------------

**\***Short term effects expressed as the number of additional persons per 1000 participants that quit smoking, loose weight, increase activity, or continue lifelong medication. Only continuous drug use was assumed to lead to effects on disease risks, the latter were different for the general population and diabetes patients and for age and baseline risk \[[@B30],[@B32]\]. Long term effects were age dependent and computed using the RIVM-Chronic Disease Model.

^†^Intervention costs only. Effects on costs of care were age dependent and computed in the RIVM-Chronic Disease Model. Earlier publications provide more details on the intervention cost estimates \[[@B27]-[@B32]\]. All estimates were adjusted to price level 2007 using consumer price indices.

^‡^Ronkers et al. \[[@B34]\]

^§^Mensink et al. \[[@B35]\]

\*\* Costs of lifetime medication use and consults were age dependent.

^††^Deakin et al. \[[@B36]\]

^‡‡^Pi-Sunyer et al. \[[@B37]\]

^§§^Effects given are the number of persons that continue lifetime medication. Effects of medication on disease risks were based on a meta-analysis \[[@B38]\]. For full details see the RIVM report by Jacobs-van der Bruggen et al. 2007 (available at <http://www.rivm.nl/bibliotheek/rapporten/260801004.pdf>).

\*\*\* Effects given are the number of persons that continue lifetime medication. Effects of medication on disease risks were based on a meta-analysis \[[@B6]\]. For full details see Jacobs-van der Bruggen et al. 2008 \[[@B30]\] and the RIVM report mentioned above.

The interventions in the general population are in principle also available for people with diabetes. However, it was assumed that the diabetes specific interventions get priority in case of overlap of target groups. Costs for the medication interventions specific for diabetes patients may differ from similar interventions in the general population, the main reason being different brands of medications typically used and cost sharing with other diabetes control consults. Effects and costs of interventions were corrected for relapse and non-adherence. For smoking, relapse was extensively modelled \[[@B33]\], while for overweight and activity, the effect of relapse was included in the final estimate of effectiveness \[[@B29],[@B31]\]. For cholesterol lowering drugs and blood pressure control medication, a correction for non-adherence was done for those that would cease medication use within two years by excluding health gains and drug related costs after these two years \[[@B30],[@B32]\].

Simulation model
----------------

The RIVM Chronic Disease Model (CDM) and its diabetes module were applied to compute the long term effects of the interventions. The CDM is a Markov-type simulation model,\[[@B20]\] and comprises epidemiological data quantifying associations between multiple risk factors and chronic diseases among which cardiovascular diseases and cancers. The CDM diabetes module simulates the Dutch diabetes population \[[@B31]\]. The CDM has been used among others to evaluate long-term outcomes for diabetes prevention and treatment \[[@B29]-[@B31]\].

Current practice in the Netherlands served as a benchmark case, so that costs and effects are to be interpreted as additional values compared to current practice. Net cumulative gains in (quality adjusted) life expectancy and net effects on the present value of health care costs were estimated over a lifetime horizon. Costs and effects were tracked until the last person of the cohort had died, for 3 age groups, 20-44 years, 45-64 years and 65 years and older. Outcomes in future years were discounted at the rates prescribed by the current Dutch guidelines for pharmacoeconomic evaluations (4% and 1.5% annually for health effects and costs respectively.) Total costs per QALY for all 12 interventions, for three age categories, for the intervention compared to usual care were estimated (cf Table [1](#T1){ref-type="table"}).

Constraints
-----------

In a third step, capacity and demand constraints were added. For each age group and risk factor, the total number of persons receiving an intervention cannot be more than the total size of the target population. For instance, it is impossible to offer more smoking cessation support courses for 65 and over than the number of smokers at that ages. This results in a set of restrictions that were added to the basic optimization model. Their values were specified for the three age categories in Table S1 (Additional file [1](#S1){ref-type="supplementary-material"}) and were derived from information about lifestyle in the Dutch (diabetes) population and availability of treatments. Furthermore, for each intervention, constraints were added to reflect that the total number of participants over all age groups for each intervention was limited by professional capacity. These restrictions will be referred to as capacity constraints (see Additional file [1](#S1){ref-type="supplementary-material"}, Table S1).

Optimization model
------------------

The optimization model used in current application may now be formally written as follows.

\(1\) $\operatorname{Max}\limits_{p^{ja}}\quad\sum\limits_{j}\sum\limits_{a}p^{ja}q^{ja}$ subject to

\(2\) $\sum\limits_{j}\sum\limits_{a}p^{ja}c^{ja} \leq b$ and *b*given.

\(3\) $\sum\limits_{a}p^{ja} \leq cap^{j}$, for all j,

\(4\) 0 ≤ *p^ja^*≤ *dem^ja^*, for all j, for all a

With:

j      Index for programs, j = 1,\...12.

a      Index for age, a = 1,..3 age groups distinguished

*p^ja^*   Number of people of age a receiving program j

b      Total available budget (Net present value over entire time horizon)

*q ^ja^*   Health effects per participant of program j for people of age a (Net present value)

*c ^ja^*   Costs of program j per participant of age a (Net present value)

*dem^ja^*   Demand restrictions for program j and age group a

*cap^j^*   Capacity constraints for program j

The simulation model provided estimates for the health effects and costs per participant (q ^ja^and c ^ja^). These were combined with relevant constraints to form the resource allocation model, which was then solved using the linear programming features of Mathematica.(routine LinearProgramming)

Constraints for demand were assumed to be age group specific, while capacity constraints were given for each program over all age groups together.

Sensitivity analyses
--------------------

The standard model was analyzed for a range of different budgets, to find optimal combinations of total health and total costs. Then, we removed the capacity constraints to estimate their effect in a second analysis. Finally, sensitivity analyses investigated the robustness of the results for different discount rates and time horizons.

Results
=======

Cost-effectiveness ratios
-------------------------

Table [2](#T2){ref-type="table"} shows the interventions in the different age categories ordered at increasing costs per QALY. For most interventions, long term cost effectiveness was lowest for the lowest age category, since at this age the full effects of prevention could be included, before any harm has been done. The exceptions were statins for diabetes patients and blood pressure treatment for the general population, reflecting that for this age category too many unnecessary cases will be treated lifelong.

###### 

Costs per QALY compared to care as usual

  --------------------------------------------------------------------------------------------------------------------------------------------
  Average costs per QALY (euro)   Age category   Target population    Intervention\
                                                                      (Short name)
  ------------------------------- -------------- -------------------- ------------------------------------------------------------------------
  1400                            20-44          General population   Minimal cessation counseling by GP (S1)

                                                                      

  1500                            20-44          Diabetes patients    Minimal cessation counseling by GP (Sd1)

                                                                      

  2700                            45-64          Diabetes patients    Minimal cessation counseling by GP (Sd2)

                                                                      

  2900                            45-64          General population   Minimal cessation counseling by GP (S2)

                                                                      

  3000                            20-44          General population   Hartslag Limburg (HL1)

                                                                      

  5400                            45-64          General population   Hartslag Limburg (HL2)

                                                                      

  5800                            20-44          Diabetes patients    LookAHEAD (LA1)

                                                                      

  5900                            20-44          Diabetes patients    X-PERT (XP1)

                                                                      

  6400                            20-44          Diabetes patients    Intensive smoking cessation counseling plus pharmacotherapy((ISd1)

                                                                      

  6700                            20-44          General population   Intensive smoking cessation counseling plus pharmacotherapy (IS1)

                                                                      

  6800                            20-44          Diabetes patients    Medication to reduce blood pressure for persons with\
                                                                      SBP \> 140 (BPd1)

                                                                      

  7400                            45-64          Diabetes patients    X-PERT (XP2)

                                                                      

  7800                            45-64          Diabetes patients    Medication to reduce blood pressure for persons with\
                                                                      SBP \> 140 (BPd2)

                                                                      

  8000                            65+            Diabetes patients    Minimal cessation counseling by GP (Sd3)

                                                                      

  8600                            45-64          General population   Intensive smoking cessation counseling plus pharmacotherapy (IS2)

                                                                      

  9200                            45-64          Diabetes patients    Intensive smoking cessation counseling plus pharmacotherapy (ISd2)

                                                                      

  9800                            45-64          Diabetes patients    Statins for all diabetes patients (Std2)

                                                                      

  10100                           45-64          Diabetes patients    LookAHEAD (LA2)

                                                                      

  10500                           65+            General population   Minimal cessation counseling by GP (S3)

                                                                      

  10900                           45-64          General population   Medication to reduce blood pressure for persons with SBP \> 140 (BP2)

                                                                      

  11000                           20-44          Diabetes patients    Statins for all diabetes patients (Std1)

                                                                      

  11200                           20-44          General population   Medication to reduce blood pressure for persons with SBP \> 140 (BP1)

                                                                      

  12900                           65+            Diabetes patients    Medication to reduce blood pressure for persons with SBP \> 140 (BPd3)

                                                                      

  16100                           65+            General population   Hartslag Limburg (HL3)

                                                                      

  16600                           65+            General population   Medication to reduce blood pressure for persons with SBP \> 140 (BP3)

                                                                      

  16600                           65+            Diabetes patients    Statins for all diabetes patients (Std3)

                                                                      

  18100                           20-44          General population   Statins for persons with total cholesterol \> 6.5 (St1)

                                                                      

  18500                           45-64          General population   Statins for persons with total cholesterol \> 6.5 (St2)

                                                                      

  19700                           65+            Diabetes patients    X-PERT (XP3)

                                                                      

  19900                           20-44          General population   SLIM (SL1)

                                                                      

  27300                           45-64          General population   SLIM (SL2)

                                                                      

  28100                           65+            General population   Statins for persons with total cholesterol \> 6.5 (St3)

                                                                      

  32300                           65+            Diabetes patients    Intensive smoking cessation counseling plus pharmacotherapy (ISd3)

                                                                      

  33200                           65+            Diabetes patients    LookAHEAD (LA3)

                                                                      

  35500                           65+            General population   Intensive counseling plus pharmacotherapy (IS3)

                                                                      

  59600                           65+            General population   SLIM (SL3)
  --------------------------------------------------------------------------------------------------------------------------------------------

For the interventions in each age category ordered at worsening cost-effectiveness. (Net present values over a lifetime horizon. Discount rates 4% for costs and 1.5% for QALYs, price level 2007.).

Based on these cost-effectiveness ratios only, low budgets would seem to be spent primarily in diabetes patients: In total 17 interventions had average cost-effectiveness below €10,000 per QALY, and 11 of these were for diabetes patients. The 13 interventions costing between €10,000 and €20,000 per QALY consisted of 5 diabetes interventions and 8 interventions for the general population. Finally, 6 interventions cost more than €20,000 per QALY, and 4 of these were for the general population. That is, interventions in the diabetes population were mostly more cost-effective than in the general population reflecting the effect of targeting to a high risk group. However, low intensity overweight and activity programs were more cost-effective in the general population. This may be explained from the relatively higher effectiveness of the general population program. It cost much less and had relatively a better effect. A possible explanation is that diabetes patients already experienced serious problems from being overweight and yet did not succeed in loosing weight, so they may need more intensive programs to successfully loose weight.

Proportion of money spent in the general population
---------------------------------------------------

Table [3](#T3){ref-type="table"} shows optimal allocations and incremental cost-effectiveness ratios for a range of total budgets. At most these 12 interventions offered the possibility to gain an additional 560,000 QALY, for about €640 per capita in additional costs over the entire time horizon. Table [3](#T3){ref-type="table"} also presents the percentages of health gains and money obtained from prevention in the general population. At low budgets, all money was optimally allocated towards this type of interventions, especially smoking cessation and overweight reduction. Moderately high budgets however (that is, more than €9 per capita, or below €100 per capita), were spent mostly on prevention in diabetes. The optimal set now additionally included increased use of statins and medication for blood pressure in diabetes patients as well as intensive overweight reduction. Finally, for very high budgets, above €100 per capital, additional medication for the general population was added. The majority of budgets were again allocated to prevention in the general population. Hence, the optimal distribution of money between interventions in diabetes patients or the general population depended on available budgets.

###### 

Optimization results for different budgets

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Budget\       Spent in general population (%)   Total health gains (QALY\*1000)   Gained in general population (%)   Incremental costs per QALY   **Changes in interventions chosen**^**i**^
  (€ \*10\^6)                                                                                                                                       
  ------------- --------------------------------- --------------------------------- ---------------------------------- ---------------------------- --------------------------------------------
  1             100                               700                               100                                €1,400                       \+ S1

                                                                                                                                                    

  10            100                               6,950                             100                                €1,400                       NA^ii^

                                                                                                                                                    

  100           89                                29,400                            90                                 €6,700                       \+ IS1, Sd1, Sd2, HL1,\
                                                                                                                                                    HL2, XP1

                                                                                                                                                    

  250           65                                50,400                            74                                 €7,400                       \+ XP2, BPd1, BPd2

                                                                                                                                                    

  500           32                                78,100                            47                                 €9,800                       \+ Sd3, Std2

                                                                                                                                                    

  750           24                                103,000                           37                                 €10,900                      \+ ISd1, LA2, BP2\
                                                                                                                                                    - Sd1

                                                                                                                                                    

  1,000         43                                126,000                           49                                 €10,900                      NA

                                                                                                                                                    

  2500          77                                264,000                           76                                 €10,900                      NA

                                                                                                                                                    

  5,000         83                                440,000                           81                                 €18,100                      \+ ISd2, BP1, BPd3, St1\
                                                                                                                                                    - Sd2

                                                                                                                                                    

  7,253         88                                561,000                           84                                 €49,300                      \+ ISd3, SL1, LA3, St2, Std1\
                                                                                                                                                    - Sd3
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Maximal health gains and incremental costs per QALY for a range of different budgets. Net present values over a lifetime horizon. Discount rates 4% for costs and 1.5% for QALYs, price level 2007. Interventions added as compared to the set chosen for the budget in the previous row are indicated by +, interventions removed are indicated by -.

^i^A list of the interventions and their abbreviations is given in Table 2.

^ii^That is, more money was spent on the same set of interventions as in the previous row

From Table [2](#T2){ref-type="table"} ranking on cost-effectiveness ratios only seemed to indicate that targeted prevention was more efficient in general. However, the optimal allocations (Table [3](#T3){ref-type="table"}) showed that due to varying sizes of target populations and capacity constraints no general a priori priority for either type of prevention existed and it depended on the size of the budget, as well as available interventions, whether most resources were spent in universal prevention or in targeted prevention or both.

Effects of supply limits
------------------------

Running the optimization model without the capacity constraints on the maximal supply of each intervention resulted in almost a doubling of maximal potential health gains from 0.56 million QALY to 0.96 million QALY. Table [4](#T4){ref-type="table"} below gives the outcomes of a model without capacity limits, for the same range of budgets as in Table [3](#T3){ref-type="table"}. The maximal total budget to be spent on the 12 interventions was of course higher and amounted to circa €1200 per capita.

###### 

Optimization results in model without capacity constraints

  Budget (€ \*10\^6)       Spent in general population (%)   Total health gains (QALY \*1000)   Gained in general population (%)   Incremental costs per QALY
  ------------------------ --------------------------------- ---------------------------------- ---------------------------------- ----------------------------
  1                        100                               700                                100                                €1,460
                                                                                                                                   
  10                       100                               6,950                              100                                €1,460
                                                                                                                                   
  100                      96                                49,600                             96                                 €3,040
                                                                                                                                   
  250                      96                                78,000                             96                                 €7,230
                                                                                                                                   
  500                      74                                113,000                            84                                 €8,510
                                                                                                                                   
  750                      73                                142,000                            81                                 €10,900
                                                                                                                                   
  1000                     55                                168,000                            68                                 €10,900
                                                                                                                                   
  2500                     70                                309,000                            73                                 €13,700
                                                                                                                                   
  5000                     77                                516,000                            78                                 €20,000
                                                                                                                                   
  7250                     78                                651,000                            78                                 €20,800
                                                                                                                                   
  10,000                   84                                801,000                            82                                 €21,700
                                                                                                                                   
  Maximal budget: 13,587   87                                958,000                            84                                 €426,000

Maximal health gains and incremental costs per QALY for a range of different budgets. Model without capacity constraints. (Net present values over a lifetime horizon. Discounted rates 4% for costs and 1.5% for QALYs, price level 2007.)

Figure [1](#F1){ref-type="fig"} shows optimal combinations of budgets and total health effects, that is, the choices that obtain most health for a given budget. The steepness of the different line segments represents the incremental cost-effectiveness ratios. In other words, they reflect the additional costs that must be paid for one additional QALY, if the extra money is spent in the most efficient way. At corner points, one or more constraints force a change in the set of programs chosen. The two lines represent the model with and without capacity constraints and illustrate the effects of these constraints. For any given budget, less health can be obtained, while the upper limit to health benefits is substantially reduced in case of capacity constraints.

![**Cost effectiveness efficiency frontiers**. model with capacity constraints (dark, solid line). model without capacity constraints (light, dashed line).](1478-7547-9-14-1){#F1}

Comparison of Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} shows that the capacity constraints reduced the percentage of the budget spent in the general population. This indicates that capacity constraints were more limiting for interventions in the general population than for interventions targeted at diabetes patients.

Sensitivity analyses
--------------------

Sensitivity analyses showed that the time horizon mattered, because at shorter time horizons, neither the full costs in life years gained, nor the full health effects could be realized. Thus, maximal total costs and maximal total health effects were smaller. Figure [2](#F2){ref-type="fig"} shows the efficiency frontiers for time horizons of 25, and 50 years, compared to the lifetime horizon chosen in the main analysis. Too short time horizons caused relevant effects to be left out of the analysis.

![**Effect of different time horizons, model with capacity constraints**. 25 years (light dotted line). 50 years (grey dashed line). lifetime horizon (black solid line, reference case).](1478-7547-9-14-2){#F2}

Furthermore, the outcomes were sensitive to the rate of discount, as is usually the case in economic evaluations of prevention, with health outcomes occurring far in the future and intervention costs having to be paid immediately. The base case discounted health effects at 1.5% and costs at 4%, which is the current Dutch standard (cf <http://www.cvz.nl>). For discount rates at 4% for both health and costs, the efficiency frontier moved inward, since the net present value of health effects decreased. For discount rates of 0% on both health and costs, it moved outward. Increasing the difference in discounting between costs and health effects, with health effects discounted at 0%, rather than 1.5%, moved the efficiency frontier outward.

Discussion
==========

The current study used a resource allocation model to analyze prevention of diabetes and its complications in the Netherlands. Optimal resource allocations were computed over a set of 12 interventions aiming to reduce the risk for diabetes and/or cardiovascular disease, either in the general population or in diabetes patients. While for small and high budgets the majority of money would go to interventions in the general population, moderately high budgets were mostly spent in diabetes patients.

Strengths of the resource allocation approach were that it was relatively straightforward to account for constraints and analyze their effects. These constraints are for instance due to limited capacity to provide interventions. Removing constraints on intervention supply increased maximal additional expenditure from €640 to €1200 per capita and almost doubled maximal potential health gains. The constraints were more limiting for prevention in the general population than for interventions in diabetes patients. This makes sense, since the group of diabetes patients is much smaller.

The model used to evaluate long term health effects took into account limited effectiveness and adherence, competing risks, and relapse. Hence, the estimates took care not to overestimate health effects. Our special attention went to the health care costs to be included in the budget allocation model. In this study, costs consisted of intervention costs plus the full long term effects of prevention on health care costs. Alternatively only intervention costs could be included in the budgets. While the latter may result in numbers that are closer to common sense ideas about the sizes of the budgets at stake, it is inconsistent from a long term perspective \[[@B21]\]. Changing to short term budgets increased the variability of choices between prevention in the general population and targeted prevention (results not shown).

Another distinctive feature of our modeling exercise is that we accounted for quality of life decreases with advancing age. This is important, since obviously most of the life years gained occur at advanced ages.

While the current results were specific for the Netherlands, the general approach could be applied to any setting. This would require either an existing disease model comparable to the RIVM chronic disease model, or a transfer of this model to the appropriate setting, replacing prevalence, incidence and mortality parameters by setting specific estimates. Furthermore, the cost estimates of the interventions, as well as the estimates of capacities and further constraints should be adjusted if they were expected to differ from the Dutch estimates.

Similar recent applications of resource allocation in diabetes and in obesity prevention have appeared in the UK and in Australia \[[@B23],[@B26]\]. The study by Segal focused on prevention in the general population, especially different types of overweight control. Indirect medical costs were not included and costs were computed per life year gained, ignoring effects on quality of life. The study by Earnshaw only considered prevention in the diabetes population. In contrast, the current study also included interventions in the general population and therefore allowed to explore the trade off between both types of prevention. Furthermore, Earnshaw used a full experimental design to directly compute results for any combination of prevention interventions. In the current paper, a simpler approach was applied with only single intervention policies modeled, assuming additive health effects. Third, Earnshaw focused on intervention costs only, which implies the implicit assumption that health care cost effects would be the same for all interventions. That is clearly not the case for interventions on overweight versus smoking cessation or statin treatment. Finally, they did not incorporate age effects on quality of life, which is important if trade-offs are made between age groups.

While a number of diabetes models have been published in recent years, \[[@B39]\] for the current application we preferred to use the RIVM Chronic Disease Model (CDM). While this model maybe less well known, all parameters estimates are accessible and the general structure of the CDM as well as relevant applications have been published in peer reviewed journals \[[@B20],[@B27]-[@B33]\]. The most important advantage of this model for our current purpose was that it allows evaluating interventions in the general population and in diabetes patients using the same model.

Some assumptions in our current study require further discussion. First of all, combinations of interventions were assumed to have no specific interaction effects, that is, the health gains in terms of life years and QALYs gained were assumed additive. This same assumption was made for instance in the global burden of disease study \[[@B40]\]. It probably implies an overestimation of total health effects if persons receive more than one intervention. This assumption is a bit more problematic in the diabetes population than in the general population. Thus the effects of the diabetes interventions may have been overestimated as compared to interventions in the general population, implying that the optimal shares of money spent in the general population might be higher than our results indicated. Second, another assumption applied in the current paper was the possibility to offer interventions to a population of variable size, by varying the budget spent on each intervention. Some resource allocation models pay specific attention to the consequences of having indivisible interventions of fixed sizes \[[@B41]\]. The optimization problem then changes into a so called integer programming problem. The question whether program size is variable or not depends on the interventions at stake. For the current interventions, it was rather easy to vary sizes by having more or less money available for them, because most of them were supply driven and addressed people that are not yet acutely ill. For curative interventions, varying program size may be more problematic, since it would imply that some actual patients would receive improper treatment.

While we did provide sensitivity analyses for the effects of discount rates, time horizon and budgetary constraints, a more extensive uncertainty analysis would improve insight into the robustness of our outcomes. This requires the use of stochastic programming techniques and we would like to address this issue in future research.

A further advantage of the resource allocation approach is that once the model has been formulated, it is easy to vary constraints and objectives, for instance on indivisible programs or equity \[[@B23],[@B24]\]. The current results on capacity constraints might help to focus efforts to extend prevention capacity to those areas where it would be most worthwhile, using the shadow prices of the constraints.

A drawback of resource allocation models may be seen in their data greediness. However, most of these data would be needed for careful priority setting anyway. The only additional requirement for a budget allocation model is that all data used are consistent and can be sensibly combined in the same model. Therefore, using a resource allocation model forces to seek for consistent, well comparable data, and that maybe considered an advantage rather than a drawback \[[@B17]\].

Conclusions
===========

Resource allocation models may help health care decision makers to integrate information about the costs, sizes, and health effects of sets of programs. Our diabetes application had U-shaped results: prevention in the general population was the best way to retain health benefits for low and high budgets, while moderate budgets would mostly be spent on prevention in diabetes patients. Targeted prevention in diagnosed patients was therefore not a priori more or less efficient than prevention in the general population. The application also showed that an additional 560 thousand QALYs may be gained by currently available interventions even when accounting for existing capacity and demand limits.
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